Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS)

Li, Ji; Larregieu, Caroline A.; Benet, Leslie Z.

doi:10.1016/s1875-5364(17)30013-4

Cited by 13 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first-pass metabolism of aspirin, a BDDCS class 1 drug 76 belonging to non-steroidal anti-inflammatory drugs (NSAIDs), also involved the enzyme activity of microbiota. It was generally considered that upper gastrointestinal tract was the main site where aspirin was absorbed, so the influence of the gut microbiota on the absorption or metabolism of aspirin would be neglected.…”

Section: The Gut Microbial Enzyme Activitymentioning

confidence: 99%

The influence of the gut microbiota on the bioavailability of oral drugs

Zhang

Han

Huang

et al. 2021

Acta Pharmaceutica Sinica B

104

View full text Add to dashboard Cite

Due to its safety, convenience, low cost and good compliance, oral administration attracts lots of attention. However, the efficacy of many oral drugs is limited to their unsatisfactory bioavailability in the gastrointestinal tract. One of the critical and most overlooked factors is the symbiotic gut microbiota that can modulate the bioavailability of oral drugs by participating in the biotransformation of oral drugs, influencing the drug transport process and altering some gastrointestinal properties. In this review, we summarized the existing research investigating the possible relationship between the gut microbiota and the bioavailability of oral drugs, which may provide great ideas and useful instructions for the design of novel drug delivery systems or the achievement of personalized medicine.

show abstract

Section: The Gut Microbial Enzyme Activitymentioning

confidence: 99%

The influence of the gut microbiota on the bioavailability of oral drugs

Zhang

Han

Huang

et al. 2021

Acta Pharmaceutica Sinica B

104

View full text Add to dashboard Cite

show abstract

“…3,54 As a consequence, such drugs tend to undergo minimal CYP-mediated metabolism after administration to humans, and are eliminated unchanged via renal or biliary secretory pathways with the active participation of drug transporters that reside on the membranes of cells that serve a barrier function. 55,56 Therefore, genetic differences that affect the activity of the transport process may be of greater significance in therapeutic outcomes in African populations where there is a high need for the use of the anti-infective drugs that are substrates for drug transporters. This review highlights that there is much less published data on drug transporters in African populations than for CYP genes, with a smaller number of studies identified from only 13 African countries; the majority of these studies had fewer than 100 participants.…”

Section: Findings In Contextmentioning

confidence: 99%

Genetic Diversity in Drug Transporters: Impact in African Populations

Rajman

Knapp²,

Hanna

2020

Clinical Translational Sci

View full text Add to dashboard Cite

Polymorphisms in drug transporters, like the adenosine triposphate‒binding cassette (ABC) and solute carrier (SLC) superfamilies, may contribute to the observed diversity in drug response in African patients. This review aims to provide a comprehensive summary and analysis of the frequencies and distributions in African populations of ABC and SLC variants that affect drug pharmacokinetics (PK) and pharmacodynamics (PD). Of polymorphisms evaluated in African populations, SLCO1B1 rs4149056 and SLC22A6 rs1158626 were found at markedly higher frequencies than in non‐African populations. SLCO1B1 rs4149056 was associated with reduction in rifampin exposure, which has implications for dosing this important anti‐tuberculosis therapy. SLC22A6 rs1158626 was associated with increased affinity for antiretroviral drugs. Genetic diversity in SLC and ABC transporters in African populations has implications for conventional therapies, notably in tuberculosis and HIV. More PK and PD data in African populations are needed to assess potential for a different response to drugs compared with other global populations.

show abstract

“…Therefore, the water-soluble phase of the extract was further investigated in the present study, in order to elaborate the potency of water-soluble bioactive materials in propolis which have polar or moderate polarity characteristics. It was expected that the bioactive materials in water-soluble propolis and bee pollen would fulfil class 1 (the bioactive materials have high solubility and extensive metabolism) or class 2 (the bioactive materials have low solubility, extensive metabolism) criteria of the Biopharmaceutical Drug Disposition and Classification System ( 17 , 18 ). Bioactive materials with class 1 or class 2 characteristics are considered as promising candidates in drug discovery and could be investigated in further research, since they have good solubility and permeability in the gastrointestinal membrane in oral administration ( 17 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

Water‑soluble propolis and bee pollen of <em>Trigona</em> spp. from South Sulawesi Indonesia induce apoptosis in the human breast cancer MCF‑7 cell line

2020

View full text Add to dashboard Cite

Bee products are best known as one of the beneficial natural products providing multiple pharmacological effects, such as antimicrobial, antiviral, anti-inflammatory and anticancer effects. The present study aimed to identify potent products derived from the stingless bee Trigona spp. from Luwu Utara (South Sulawesi, Indonesia), focussing on the water-soluble extract of propolis and bee pollen, against the proliferation of the human breast cancer MCF-7 cell line. The results from DPPH (2,2-diphenyl-1-picrylhydrazyl) method of antioxidant assay revealed that water-soluble propolis and bee pollen had high antioxidant activity, with half-maximal effective concentrations against DPPH radicals of 1.3 and 0.4 mg/ml, respectively. Additionally, water-soluble propolis and bee pollen exhibited a significant antiproliferative activity in MCF-7 cells, with IC 50 values of 10.8±0.06 and 18.6±0.03 mg/ml, respectively (P<0.05). Significant cytotoxic effects were observed after 24 h of treatment via microscopic and flow cytometric analysis, where a morphological change toward late apoptosis was observed. By contrast, honey had low antioxidant activity and no antiproliferative effect in MCF-7 cells. The water-soluble propolis also exerted its antiproliferative effect in the human keratinocyte HaCaT cell line. The antiproliferative activity was similar (P>0.05) at 24 and 48 h of treatment, with IC 50 at 2.7±0.06 mg/ml and <0.4 mg/ml, respectively. Notably, bee pollen was less toxic to HaCaT cells after 24 h of treatment than the water-soluble propolis, with IC 50 >50 mg/ml. Its antiproliferative activity was significantly increased after 48 h of treatment, with IC 50 at 9.6±0.07 mg/ml (P<0.05). In addition, similar to other poplar propolis, the high-performance liquid chromatography-ultraviolet and electrospray ionisation mass spectrometry analyses revealed that caffeic acid phenethyl ester was not the main bioactive compound of the samples examined. Furthermore, two major proteins (between ~50 and 75 kDa) were identified in the water-soluble propolis and bee pollen. The present results suggested that water-soluble propolis and bee pollen may have the potential to be elaborated further as a breast anticancer therapy.

show abstract

Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS)

Cited by 13 publications

References 33 publications

The influence of the gut microbiota on the bioavailability of oral drugs

The influence of the gut microbiota on the bioavailability of oral drugs

Genetic Diversity in Drug Transporters: Impact in African Populations

Water‑soluble propolis and bee pollen of <em>Trigona</em> spp. from South Sulawesi Indonesia induce apoptosis in the human breast cancer MCF‑7 cell line

Contact Info

Product

Resources

About